Battling Steroid Excess with Sparrow Pharmaceuticals’ David Katz

Health Innovation Matters

Contenuto fornito da Michael Levin-Epstein, Robin L. Smith, MD, and MBA. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Michael Levin-Epstein, Robin L. Smith, MD, and MBA o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

2y ago 34:25

MP3•Pagina principale dell'episodio

Fetch error

Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on August 22, 2024 13:33 (3M ago)

What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.

Michael chats with David Katz, chief scientific officer and founder of Sparrow Pharmaceuticals. Prior to founding Sparrow, David was a pharmaceutical R&D leader at Abbott and AbbVie, where he led clinical development and drug discovery teams and was a personalized medicine pioneer. He is currently an entrepreneur-in-residence at Oregon Health & Science University.

David held post-doctoral fellowships in immunology at the Universities of Chicago and Michigan and earned a B.A. in Chemistry at Pomona College and a Ph.D. in Molecular Biophysics and Biochemistry from Yale University. In this episode, David discusses the creation of Sparrow, the company’s work in developing new medicines for patients who have experienced the effects of excess steroids, and how, in his view, developing drugs is just as much of an art as it is a science.

This episode is sponsored by Sparrow Pharmaceuticals, sparrowpharma.com.

83 episodi

#Fitness #Alternative Health #Jodey Smith #MBA #Robin Smith